Pentagastrin Research Index

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.

Erlandson KM, Gustafson L, Johnson JE et al.

BMJ Open·2026·Human·GH Activity·PubMed →

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Dominikowski A, Rękoś Z, Olejarz M et al.

Front Endocrinol (Lausanne)·2026·Human·GH Activity·PubMed →

Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.

Fleseriu M, Biller BMK, Webb SM et al.

Pituitary·2026·Human·GH Activity·PubMed →

The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.

Stewart CE, French KP, Wright TJ et al.

eNeurologicalSci·2026·Animal·PubMed →

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.

Beach R, Tims-Cook Z, McGary CS et al.

Clin Infect Dis·2026·Animal·GH Activity, Weight Loss·PubMed →

Selected Industry Highlights From IDWeek 2025.

Parienti JJ, Yang SS, Grinspoon S

Clin Infect Dis·2026·Animal·Weight Loss·PubMed →

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.

Chege BM, Mwangi PW, Githinji CG et al.

Braz J Med Biol Res·2026·Animal·PubMed →

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

Uçaktürk E, Nemutlu E

J Pharm Biomed Anal·2026·Animal·GH Activity·PubMed →

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Ellis RJ, Vaida F, Hu K et al.

J Infect Dis·2025·Human·GH Activity·PubMed →

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Mihalache A, Volfson E, Huang R et al.

Cureus·2025·Animal·PubMed →

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

Russo SC, Ockene MW, Arpante AK et al.

AIDS·2024·Human·GH Activity·PubMed →

Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.

Chege BM, Mwangi PW, Githinji CG et al.

PLoS One·2024·Animal·Metabolic Syndrome, Weight Loss·PubMed →

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Thomas A, Walpurgis K, Thevis M

J Mass Spectrom·2024·Animal·GH Activity·PubMed →

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Rahman F, McLaughlin T, Mesquita P et al.

J Clin Transl Sci·2023·Human·PubMed →

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

Cristea CD, Radu M, Toboc A et al.

Anal Biochem·2023·Animal·PubMed →

Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways.

Fourman LT, Stanley TL, Ockene MW et al.

J Infect Dis·2023·Animal·Liver Fat (MASLD), Liver Protection·PubMed →

Approach to the Patient With Lipodystrophy.

Fourman LT, Grinspoon SK

J Clin Endocrinol Metab·2022·Human·Glycemic Control, Weight Loss·PubMed →

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Stanley TL, Fourman LT, Wong LP et al.

Clin Infect Dis·2021·Human·GH Activity, Liver Fat (MASLD)·PubMed →

Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.

Stanley TL, Fourman LT, Zheng I et al.

J Clin Endocrinol Metab·2021·Human·Glycemic Control, GH Activity, Liver Fat (MASLD)·PubMed →

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Fourman LT, Stanley TL, Zheng I et al.

Clin Infect Dis·2021·Human·PubMed →

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Fourman LT, Billingsley JM, Agyapong G et al.

JCI Insight·2020·Human·GH Activity, Liver Protection, Liver Fat (MASLD)·PubMed →

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley TL, Fourman LT, Feldpausch MN et al.

Lancet HIV·2019·Human·PubMed →

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Adrian S, Scherzinger A, Sanyal A et al.

J Frailty Aging·2019·Human·GH Activity, Muscle Recovery·PubMed →

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Braun LR, Feldpausch MN, Czerwonka N et al.

Growth Horm IGF Res·2017·Human·Liver Fat (MASLD), GH Activity, Anti-Inflammatory·PubMed →

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons DR, Miller S, Mamputu JC

PLoS One·2017·Human·Glycemic Control, GH Activity·PubMed →

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC et al.

PLoS One·2015·Human·GH Activity·PubMed →

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO et al.

J Pharmacokinet Pharmacodyn·2015·Human·GH Activity·PubMed →

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO et al.

Clin Pharmacokinet·2015·Human·Weight Loss, GH Activity·PubMed →

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J et al.

JAMA·2014·Human·Liver Fat (MASLD), GH Activity, Liver Protection·PubMed →

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Makimura H, Murphy CA, Feldpausch MN et al.

J Clin Endocrinol Metab·2014·Human·GH Activity, Weight Loss·PubMed →

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

Friedman SD, Baker LD, Borson S et al.

JAMA Neurol·2013·Human·Longevity, GH Activity·PubMed →

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

Glesby MJ, Albu J, Chiu YL et al.

PLoS One·2013·Human·Glycemic Control, GH Activity·PubMed →

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura H, Feldpausch MN, Rope AM et al.

J Clin Endocrinol Metab·2012·Human·Cardiovascular Risk, GH Activity·PubMed →

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Baker LD, Barsness SM, Borson S et al.

Arch Neurol·2012·Human·PubMed →

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C et al.

Clin Infect Dis·2012·Human·GH Activity·PubMed →

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.

Makimura H, Stanley TL, Chen CY et al.

Growth Horm IGF Res·2011·Human·GH Activity, Weight Loss·PubMed →

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC et al.

AIDS·2011·Human·GH Activity, Anti-Inflammatory·PubMed →

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar T, Mechanic O, Fehmie DA et al.

HIV Med·2011·Human·GH Activity, Metabolic Syndrome, Muscle Recovery·PubMed →

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy.

Mateo MG, Gutiérrez MDM, Domingo P

Expert Rev Endocrinol Metab·2011·Human·PubMed →

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D et al.

J Clin Endocrinol Metab·2010·Human·GH Activity·PubMed →

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC et al.

J Acquir Immune Defic Syndr·2010·Human·GH Activity·PubMed →

Therapeutic trial of growth hormone releasing factor in HIV patients.

Winslow DL

AIDS Alert·2008·Human·GH Activity·PubMed →

Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.

Berger D

Posit Aware·2008·Human·GH Activity·PubMed →

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC et al.

AIDS·2008·Human·GH Activity·PubMed →

Approach to the human immunodeficiency virus-infected patient with lipodystrophy.

Brown TT

J Clin Endocrinol Metab·2008·Human·Cardiovascular Risk, GH Activity, Glycemic Control·PubMed →

Effects of growth hormone-releasing factor in HIV-infected patients.

Malgarini RB, Pimpinella G

N Engl J Med·2008·Human·PubMed →

Manipulation of the growth hormone axis in patients with HIV infection.

Blackman MR

N Engl J Med·2007·Human·PubMed →

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K et al.

N Engl J Med·2007·Human·Cardiovascular Risk, GH Activity·PubMed →

Side effects and complications. Tesamorelin--results from Phase III.

TreatmentUpdate·2007·Human·GH Activity·PubMed →

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Falutz J, Allas S, Kotler D et al.

AIDS·2005·Human·GH Activity·PubMed →